USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/12374
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChiuzan, Adrian-Stefan-
dc.contributor.authorStanca, Mihai-
dc.date.accessioned2020-10-29T08:05:09Z-
dc.date.available2020-10-29T08:05:09Z-
dc.date.issued2016-
dc.identifier.citationCHIUZAN, Adrian-Stefan, STANCA, Mihai. Adherence to tyrosine kinase inhibitors treatment in patients with chronic myeloid leukemia: single institution experience. In: MedEspera: the 6th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2016, p. 173.en_US
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/12374-
dc.descriptionUniversity of Medicine and Pharmacy, Targu Mures, Romania, The 6th International Medical Congress for Students and Young Doctors, May 12-14, 2016en_US
dc.description.abstractIntroduction: Treatment adherence is an important element in the management of every chronic disease. For the patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI) the remarkable benefits brought by the medication may be significantly undermined by the patient low adherence to treatment. Materials and methods: We conducted a qualitative and observational study, which was performed between October 2015 and December 2015, on patients diagnosed with CML under treatment with TKI at I-st Medical Clinic-Hematology, Clinical Emergency County Hospital Targu Mures, Romania. The sampling of patients was simple-random, consisting of 32 patients with CML-chronic phase, >18 years old, with >12 months of treatment with TKI, median age was 55 years, 67.47% of the patients were males and 62.5% of the patients were treated with imatinib 400 mg/QD. Physician-reported adherence (observed adherence) was evaluated, for the last 3 months, using the Proportion of Days Covered (PDC) method and patient-reported adherence (experienced adherence) using a self-reporting questionnaire with 10 items regarding adherence to treatment; demographic data were collected too. The following statistical analysis was used: descriptive statistic, Fisher Exact test, unpaired t-test. Results: PDC was <0.9 (low adherence) in 3 patients and 0.9-1 in 5 patients (medium adherence); Total lower adherence (low + medium) was 25%, patients being younger (p=0,044), but adherence was not correlated with gender, TKI treatment length, urban/rural place of living (p>0.05). 46.88% of the patients admit omission of doses, 73.33% of them attributing it to forgetfulness (33.33% rarely forgot, 40% sometimes), the other 26.66% to medication adverse effects or to a sense of feeling sick. Conclusion: PDC estimation of adherence was more optimistic compared to experienced adherence. Due to the unavoidable errors Associated with patient self-report, the rate of non-adherence is probably underestimated. Because the adherence to chronic medication in general and to TKI in particular is multifactorial, further quantitative, multiparameter and multicenter studies are necessary.en_US
dc.language.isoenen_US
dc.publisherMedEsperaen_US
dc.subjectchronic myeloid leukemiaen_US
dc.subjecttreatment adherenceen_US
dc.subjecttyrosine kinase inhibitorsen_US
dc.titleAdherence to tyrosine kinase inhibitors treatment in patients with chronic myeloid leukemia: single institution experienceen_US
dc.typeArticleen_US
Appears in Collections:MedEspera 2016

Files in This Item:
File Description SizeFormat 
ADHERENCE_TO_TYROSINE_KINASE_INHIBITORS_TREATMENT_IN.PDF6.72 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback